Matt Zielinski writes, “I recently learned that you collect images of science tattoos. Attached is a photo of a tattoo I recently had done. I wanted a biomechanical theme to the piece with a special focus on the material chemistry that could potentially be used if this piece of sci-fi comes to life. The tattoo starts on the left with simple atoms and molecules (water, NO3) and evolves into the organic chains. Those macromolecules are PEEK, PEI, and polysulfone, all of which are engineered polymers commonly used in the medical device industry today. They can also withstand incredibly high temperatures and are very strong materials. The ball-and-stick macromolecule is intended to be ADP to demonstrate a synthesis of engineered and natural chemistry in the final product, the half-machine, half-woman face at the top right.

“I am a chemical engineer by education who works in the specialty polymer industry. A lot of the projects I work on were the inspiration for this tattoo and I believe that the technology to produce the biomechanical woman is not so far fetched as many would think.”

You can see the rest of the Science Tattoo Emporium here or in my book, Science Ink: Tattoos of the Science Obsessed.

Originally published May 19, 2013. Copyright 2013 Carl Zimmer.

It’s easy to forget sometimes that evolution is always a work in progress. We contemplate the eye or look upon an oak tree, and ask, how could they be any better? Somehow, in those moments of awe, we forget about detached retinas and sudden oak death. The evolutionary race is not in fact won by the perfect, but by the good-enough. And it just so happens that one of the best illustrations of evolution’s mediocrity is unfolding in front of us right now.

This episode of evolution is entirely of our own doing. In 1936, a chemical called pentachlorophenol went on the market. It was hugely popular as a way to preserve telephone poles and lumber against fungi and termites. Unfortunately, it also turned out to be toxic to humans, and once it got into the soil it could contaminate the ground for years. That’s because the molecule–five chlorine atoms decorating a ring of carbon atoms–had not previously existed in nature. Microbes had not evolved to feed on it before. It was as toxic to them as it was to us.

Continue reading “Mediocre Poison Eaters And The Imperfection of Evolution”

It’s Thursday, and that means that I’m publishing my next piece for Matter, my weekly column for the New York Times. Today, I take a look at dogs. Last month I wrote in the Times about cognitive scientists playing games with dogs to probe their behavior. But that’s just part of the story of canine research these days. There are also geneticists out there looking at the same question from a different perspective. They want to find the genes that evolved over the past 30,000 years or so to turn the brain of a wolf into the brain of a dog. The answers are now starting to emerge, and they’re fascinating. They may, in fact, tell us a lot about how we became humans. Check it out!

Originally published May 16, 2013. Copyright 2013 Carl Zimmer.

In today’s New York Times, the actress Angelina Jolie published a remarkably forthcoming op-ed about getting a double mastectomy. Jolie carries a variant of a gene called BRCA1 that makes women highly likely to develop breast and ovarian cancer. Her mother, who also carried the variant, died of ovarian cancer at age 56. Like a number of other women with her condition, Jolie decided to get a mastectomy as a preventative measure.

A number of studies have shown that bilateral risk-reducing mastectomies (the official term) do indeed reduce the risk of breast cancer in women with the BRCA1 mutation. In a study published last month in Annals of Oncology, a team of Dutch medical researchers tracked 570 women with BRCA1 (or a mutation in the related gene BRCA2). At the start of the study, all the women were healthy; 212 of them later chose to get risk-reducing mastectomies. Over the next few years, the researchers followed their progress. Sixteen percent of the women who didn’t get risk-reducing mastectomies developed breast cancer; of the women who went Jolie’s route, none did.

Continue reading “Tracing Breast Cancer’s History”